Related Experiment Video
Updated: Feb 19, 2026
08:56
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
54.8K
Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET
Angela Vitrano1, Massimiliano Sacco1, Rosamaria Rosso2
1Campus of Haematology Franco and Piera Cutino, AOOR Villa Sofia-V. Cervello, Palermo, Italy.
European Journal of Haematology
|November 3, 2017
Summary
Liver iron concentration (LIC) can vary over time with chelation therapy, even in patients with hemochromatosis. Serum ferritin levels may not always reflect changes in LIC.
Area of Science:
- Hematology
- Radiology
- Medical Diagnostics
Background:
- The liver is the primary site for iron storage, and liver iron concentration (LIC) is a key indicator of total body iron.
- Magnetic Resonance Imaging (MRI-R2) is an accurate method for measuring LIC.
- The Liver Iron Cutino Network (LICNET) was established to diagnose liver iron overload in patients with hemochromatosis and other hematological disorders.
Purpose of the Study:
- To investigate the longitudinal variations in LIC measurements over time.
- To analyze these variations across different chelation regimens in patients with hemochromatosis.
Main Methods:
- A cross-sectional study involving 130 patients from 9 Italian centers within the LICNET.
- LIC measurements were compared at two time points (T0 and T1) using t-tests and/or Wilcoxon tests.
Main Results:
- LIC showed a significant decrease from MRI1 to MRI2, though with considerable variance (median change -0.8 mg Fe/g dw).
- Approximately 7.7% of patients transitioned from a high-risk LIC category (>15 mg Fe/g dw) to an intermediate-risk category (7-15 mg Fe/g dw).
- Median changes in LIC and their correlation with serum ferritin levels under various chelation regimens were documented.
Conclusions:
- Longitudinal variations in LIC are possible and occur across different chelation regimens.
- Serum ferritin levels are not consistently reliable for estimating changes in LIC.
Related Concept Videos
01:28Esophageal Varices-II: Clinical Features and Management
647
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
647
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
213
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
213
00:56Extraction: Advanced Methods
1.2K
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
1.2K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
259
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
259